DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1889)

Cholangiocarcinoma | Epidemiology | Mature Markets Data

Cholangiocarcinoma | Epidemiology | Mature Markets Data

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of cholangiocarcinoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at the first line of therapy is also forecast across the major mature pharmaceutical markets.

DRG Epidemiology's cholangiocarcinoma forecast will answer the question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of soft tissue sarcoma over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following cholangiocarcinoma subpopulations:

  • Diagnosed incident cases— intrahepatic and extrahepatic cholangiocarcinoma
  • Diagnosed prevalent cases — intrahepatic and extrahepatic cholangiocarcinoma.
  • First-line drug-treatable cases – intrahepatic and extrahepatic cholangiocarcinoma
  • … and more (details available on request).

Note: Coverage may vary by country.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
      • Overview
        • Incidence of Intrahepatic Cholangiocarcinoma per 100,000 per Year Among People of All Ages in 2018 and 2038
        • Incidence of Extrahepatic Cholangiocarcinoma per 100,000 per Year Among People of All Ages in 2018 and 2038
        • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Intrahepatic Cholangiocarcinoma over the Next Twenty Years
        • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Extrahepatic Cholangiocarcinoma over the Next Twenty Years
        • Resectability Status of Cholangiocarcinoma Cases Across the Countries Under Study
    • Epidemiology Data
    • Methods
      • Newly Diagnosed Incidence
      • Stage Distribution
      • Recurrent Incidence
      • Diagnose Prevalence
      • Drug-Treatable Population
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: December 2018
  • Author(s): Nishant Kumar, MPH; Johnson Olabisi, MBBS, MSc
  • Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.

  • Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space. Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.  

Purchase Report

Recent reports:
You may also be interested in: